Psychotherapy of psychotic disorders Abstract. The efficacy of psychotherapy for individuals with psychotic disorders is well documented and its implementation is recommended by international guidelines. Goals of psychotherapeutic interventions are reduction of symptoms, prevention of relapse, improvement of cognitive, emotional and social functioning, social integration and participation, and enhancement of quality of life as well as self-perception. Cognitive-behavioral and family interventions, cognitive and social trainings as well as psychoeducation are particularly recommended according to the literature. Fundamental factors for a favorable treatment result are a profound therapeutic relationship, a therapeutic setting according to patients' needs, and a specific coordination with other interventions within the individual treatment concept. The implementation of evidence-based psychotherapeutic interventions for individuals with psychotic disorders in clinical routine practice seems to be most challenging for future mental health service organization and research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/0040-5930/a000968 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anhedonia relates to reduced striatal reward anticipation in depression but not in schizophrenia or bipolar disorder: A transdiagnostic study.
Cogn Affect Behav Neurosci
January 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Neurosciences | CCM, Berlin, Germany.
Anhedonia, i.e., the loss of pleasure or lack of reactivity to reward, is a core symptom of major psychiatric conditions.
View Article and Find Full Text PDFManagement of Psychosis and Schizophrenia by Primary Care GPs: A Cross-Sectional Study in Spain.
J Prim Care Community Health
January 2025
Instituto de Investigación Biomédica de Málaga, Málaga, Spain.
Aim: To investigate the detection and initial management of first psychotic episodes, as well as established schizophrenia, within the primary care of the Andalusian Health System.
Background: Delay in detecting and treating psychosis is associated with slower recovery, higher relapse risk, and poorer long-term outcomes. Often, psychotic episodes go unnoticed for years before a diagnosis is established.
Trends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019-2023.
Psychiatr Serv
January 2025
Department of Psychiatry and Behavioral Neuroscience (Bunting, Gray), Department of Pharmacy (Gray), and Pritzker School of Medicine (Chalmers), University of Chicago, Chicago; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Cotes); Department of Psychiatry, University of Washington, Seattle (Chalmers); Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor (Nguyen).
Objective: Long-acting injectable antipsychotics (LAIAPs) enable safe and effective long-term management of chronic psychotic disorders but are underused in clinical practice. The authors examined whether Medicare formulary restrictions (prior authorization [PA] or step therapy) impose barriers to LAIAP uptake.
Methods: The authors analyzed formulary restrictions and patient cost-sharing for several LAIAPs and estimated the percentage of plans (N=2,494 were available per year) applying formulary restrictions.
Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.
Psychiatry Res
January 2025
South Carolina Department of Mental Health, 220 Executive Dr, Greer, SC 29651, United States; Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 15 Medical Park, Suite 301, Columbia, SC 29203, United States.
Although long-acting injectable antipsychotics (LAIs) are an important pharmaceutical option in the management of schizophrenia and related disorders, little is known about patient characteristics related to LAI use in real-world outpatient settings. We analyzed electronic medical records from 41,401 patients who received psychiatric services from one of 16 regional mental health centers operated by the South Carolina Department of Mental Health in 2022. We compared the use of first- and second-generation LAIs and oral antipsychotics by sociodemographic (age, gender, race/ethnicity, zip code, payment source) and clinical characteristics (psychiatric diagnoses, service use).
View Article and Find Full Text PDFTranscutaneous vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis.
Front Aging Neurosci
January 2025
Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Transcutaneous vagus nerve stimulation (tVNS) has emerged as a novel noninvasive adjunct therapy for advanced Parkinson's disease (PD), yet no quantitative analysis had been conducted to assess its therapeutic effect.
Objectives: This review aimed to investigate the efficacy of tVNS on motor function, other potential clinical targets and its safety in various treatment conditions.
Methods: We searched six databases for randomized controlled trials (RCTs) that involved treating PD patients with tVNS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!